

IN brief

NCATS launches

In December, President Barack Obama signed an appropriations bill authorizing the new National Center for Advancing Translational Science (NCATS) at the National Institutes of Health (NIH) and setting its first budget at \$576.5 million for fiscal year (FY) 2012. The new Center, proposed in 2010 by NIH director Francis Collins to support translational efforts has been controversial among scientists in academia and industry from the start. However, Biotechnology Industry Organization (BIO) president Jim Greenwood calls it “potentially a good thing” for the biotech industry in terms of its avowed goal of moving therapeutic products more rapidly into the hands of doctors and their patients. “It’s a work in progress—a good idea,” he says, but must be “done in the right way.” Ramping up federal support for translational research is “very important,” says H. Thomas Watkins, president and CEO of Human Genome Sciences in Rockville, Maryland, who now chairs the BIO board of directors. Although the bulk of funding for NCATS in FY 2012 is carved from established NIH programs, \$10 million in new funds are allocated to its Cures Acceleration Network (CAN). The CAN program was established in 2010 to help bridge the so-called ‘valley of death’, between basic and clinical research. It is situated within NCATS and is authorized to issue grants to biotech companies. *Jeffrey L. Fox*

BASF moves GM crop research to US

BASF Plant Science is relocating from its European headquarters to the US, a move prompted by the European public’s hostility to genetically modified (GM) crops, its president Peter Eckes said. The German company is also cancelling the development and commercialization of all projects destined solely for the European market and in future will concentrate on markets in America and Asia. “The political and regulatory climate in Europe is unwelcoming at this moment—this is a political failure,” says Carel du Marchie Sarvaas, director of advocacy group EuropaBio in Brussels. In 2010, the European Commission approved BASF’s Amflora, a GM blight-resistant potato for industrial use. The road to approval took 13 years, during which the company had to deal with protestors and sabotage to test sites in Germany. BASF will continue the regulatory process for three breeds of potato already in the European pipeline but will halt work on a wheat variety resistant to fungal disease. Despite moving its Limburgerhof headquarters in Germany, BASF is not pulling out of Europe completely and will retain offices in Ghent, Belgium, and in Berlin. Another GM crop developer, Bayer CropScience of Monheim, Germany, has no plans to leave Europe and will retain an active research program in Ghent. Julian Little, Bayer’s UK spokesperson in Cambridge, says that Europe “remains an excellent place to do research but commercialization of such technology in Europe remains problematic.” *Lucas Laursen*

HIV neutralizing antibodies reignite interest in vaccine

Patient stratification of the results of the 16,000-participant RV144 trial of a prime boost HIV vaccine in Thailand has revealed the binding antibody linked to protection against the lentivirus in a proportion of participants. Taken together with several broadly HIV-neutralizing antibodies that have recently been identified, interest is growing in exploiting the epitopes that elicit such antibodies as the basis for new vaccine opportunities. As yet, however, companies are waiting to see whether public efforts can provide more clinical evidence of potency before reentering the HIV vaccine space.

At the AIDS Vaccine Conference in Bangkok last September, scientists from the US Military HIV Research Program released the results of their analysis of RV144. In 2009, the trial had caused a stir by showing that a prime-boost regimen of two recombinant vaccine candidates—a canarypox vector-based primer ALVAC-HIV vCP1521 from Sanofi Pasteur of Lyon, France, followed by a protein boost with AIDSVAX B/E, a bivalent recombinant version of HIV’s gp120 surface protein from VaxGen (now part of diaDexus of Brisbane, California)—lowered the rate for HIV infection by ~31%, but did not affect viral load. The aim of the new analysis was to determine how the vaccine regimen provided its modest level of protection against HIV to certain individuals.

After analyzing blood samples collected from volunteers in the trial, the researchers identified two antibody responses: one correlated with a reduced risk of HIV infection, and the other with an increased risk. In the first case, vaccinated trial participants whose blood contained an IgG antibody that recognizes a portion of HIV’s outer envelope—the V2 loop—were 43% less likely to acquire HIV than volunteers whose immune systems did not generate this antibody response. In the second, vaccinated volunteers in the trial who developed IgA antibodies that targeted the HIV envelope were 54% more likely to become HIV infected, suggesting that these antibodies reduced the protective effect of the vaccines.

The clues—correlates of risk, rather than correlates of immunity—are starting points for further basic research, rather than validated targets for biotech companies. “Right now scientists are trying to work out if they can get any hint of what the correlate of immunity was in those people who were protected,” says Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which oversees HIV research for the US National Institutes of Health (NIH). “When that gets worked out, the approach is going to be developing immunogens that will induce that type of an immunogenic response,” he says. “That’s where biotech companies would come in.”



Protective responses found in some patients taking part in the Thai phase 3 trials for RV144 have yielded molecular clues that could be further exploited.

Karen Kasmauski/Getty Images

Erratum: Reinventing clinical trials

Malorye Allison

Nat. Biotechnol. 30, 41–49 (2012); published online 9 January 2012; corrected after print 11 May 2012

In the version of the article originally published, the ExoInTouch product being used by Pfizer in its virtual trial for overactive bladder (OAB) is eDiary, not Recruit, which allows patients to report through mobile phone or internet portals. The Recruit technology is being used in other studies. The text references to Recruit have been replaced with an explanation of eDiary. Instead of “new technology to recruit patients faster and in a more standardized fashion,” the text now reads, “new technology to allow home-based clinical trial data reporting.” Instead of “Recruit’ text messaging technology in a pilot study” for Detrol, the text now reads, “eDiary’ tool in a Phase 4 trial, called Research on Electronic Monitoring of OAB Treatment Experience.” Additional explanation has been added, including “Patients can respond to simple questionnaires (Fig. 3) via their mobile phones or home computers. If they delay in responding, a reminder can be sent.” And for space reasons, other text relating to Recruit, “The tool is integrated with Pfizer’s volunteer database and allows immediate text message–based communication and assessment of a subject’s suitability within 5–10 min” and “It can also be used to send protocol-specific messages to patients already enrolled in trials” was deleted. In addition, it should have been noted that Eric Westin, who was interviewed while senior director of Lilly Oncology, had left the company. The errors have been corrected in the HTML and PDF versions of the article.

Erratum: Parallel genome universes

Tom Misteli

Nat. Biotechnol. 30, 55–56 (2012); published online 9 January 2012; corrected after print 7 June 2012

In the version of this article initially published, the volume number and year of reference 2 should have been 30 and 2012, and not 29 and 2011, respectively. The errors have been corrected in the HTML and PDF versions of the article.

Erratum: BASF moves GM crop research to US

Lucas Laursen

Nat. Biotechnol. 30, 204 (2012); published online 7 March 2012; corrected after print 7 June 2012

In the version of this article initially published, BASF’s Amflora, a genetically modified potato for industrial use, was mistakenly said to be blight resistant when it is not. The error has been corrected in the HTML and PDF versions of the article.

Erratum: In Their Words

Nat. Biotechnol. 30, 203 (2012); published online 7 March 2012; corrected after print 7 June 2012

In the version of this article initially published online, Craig Thompson was incorrectly identified as the president of Rockefeller University. He is the president of Memorial Sloan-Kettering Cancer Center in New York. The error has been corrected for the PDF version of this article.

Corrigendum: Performance comparison of whole-genome sequencing platforms

Hugo Y K Lam, Michael J Clark, Rui Chen, Rong Chen, Georges Natsoulis, Maeve O’Huallachain, Frederick E Dewey, Lukas Habegger, Euan A Ashley, Mark B Gerstein, Atul J Butte, Hanlee P Ji & Michael Snyder

Nat. Biotechnol. 30, 78–82 (2012); published online 18 December 2011; corrected after print 7 June 2012

In the version of this article initially published, the accession code to obtain raw sequence data was given as SRA045736.2; the correct code is SRA045736. The error has been corrected in the HTML and PDF versions of the article.

Corrigendum: Performance comparison of benchtop high-throughput sequencing platforms

Nicholas J Loman, Raju V Misra, Timothy J Dallman, Chrystala Constantinidou, Saheer E Gharbia, John Wain & Mark J Pallen

Nat. Biotechnol. 30, 434–439 (2012); published online 22 April 2012; corrected online 23 April 2012; corrected after print 7 June 2012

In the version of this article initially published online, in the Online Methods “Ion Torrent Sequencing” section, the sentence beginning with “Ten milligrams of this DNA was fragmented with a Bioruptor instrument...” should have read “Ten micrograms...” and in the “454 GS Junior sequencing” section, “(500 total)” should have read “(500 ng total).” The errors have been corrected in the PDF and HTML versions of this article.